Vaccinology in the Age of Pandemics:
COVID-19 Lessons & Response

Date: June 15–16, 2020
Time: 3:00–6:00PM GMT

Along with clean water and antibiotics, vaccination has allowed mankind to conquer the infectious diseases that used to eradicate about 50% of children. Over the last century, vaccination has also extended life expectancy from under 50 to over 80 years of age. Now that the most important vaccines for infants and children are available, vaccination faces new challenges with the intent to bring the benefits of vaccines to other age groups, emerging infections, antimicrobial resistance, diseases that afflict low-income countries, and to improve therapies against chronic infectious diseases, cancer, autoimmune and neurodegenerative diseases. This new vaccine ambition is supported by the incredible advances in science and technology that make it technically possible to develop vaccines against many new targets and by innovative approaches to vaccine development for emerging infections and for diseases of low-income countries. The technologies that are transforming vaccinology are structure-based design, adjuvants, nucleic acid vaccines (especially RNA), viral vectors, systems biology, and controlled human infections. They are supported by scientific advances in human immunology, genomics, synthetic biology, molecular structure of antigens and antigen-antibody complexes, germinal centers, and microbiome. Conference participants will be exposed to the multidisciplinary technologies that are transforming vaccinology, including the efforts of CEPI, Bill and Melinda Gates Foundation and Wellcome Trust, to change the way vaccines are developed.



Program Details

Keynote Speaker

Anthony S. Fauci, MD
Director, NIAID/NIH
Transforming Vaccinology: Considerations for the Next Decade

Live ePanel Disucssion

Galit Alter, Rino Rappuoli, Catherine Ju-Ying Wu and Gabriel D. Victora
Transforming Vaccinology: The Next 20 Years

Speaking at this eSymposia

Neil P. King
University of Washington, USA
Structure-Based Design of Novel Nanoparticle Vaccine Platforms

Barney S. Graham
NIAID, National Institutes of Health, USA
Immunogen Design Strategies for Covid, RSV, Influenza and Other Enveloped Viruses

Gabriel D. Victora
Rockefeller University, USA
Clonal and Cellular Dynamics in Germinal Centers

Robert A. Seder
NIAID, National Institutes of Health, USA
Immunity After Intravenous Delivery of Antigens

Federica Sallusto
Università della Svizzera Italiana & ETH Zurich
Antigen Specific T Cell Diversity

Yasmine Belkaid
NIAID, National Institutes of Health, USA
Microbiome and Immunity

Galit Alter
Ragon Institute of MGH, MIT, and Harvard, USA
System Serology

Antonio Lanzavecchia
Institute for Research in Biomedicine, Switzerland
Human Monoclonals for Covid Passive Immunization and Antigen Discovery

Hedda Wardemann
German Cancer Research Center, Germany
Dissecting Antibody Responses to Plasmodium Falciparum Circumsporozoite Protein for the Development of a Malaria Vaccine

Catherine Ju-Ying Wu
Dana-Farber Cancer Institute, USA
Vaccines Against Tumor Neoantigens

Richard Hatchett
Coalition for Epidemic Preparedness Innovations, CEPI, UK
CEPI approach to emerging infections

Rino Rappuoli
GlaxoSmithKline Vaccines, Italy
Transforming Vaccinology

Included in Registration